Company news

BioAtla, Inc. news in 2024

BioAtla, Inc.'s news releases, calls and decks from 2024, newest first.

View company

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

December 19, 2024

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

December 15, 2024

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

December 9, 2024

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

November 6, 2024

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

October 30, 2024

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

October 3, 2024

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

September 30, 2024

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

September 22, 2024

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European...

September 15, 2024

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

September 8, 2024

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

August 27, 2024

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

August 7, 2024

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

July 31, 2024

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

July 24, 2024

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

July 22, 2024

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

June 26, 2024

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 28, 2024

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2024

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 13, 2024

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 5, 2024

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2024

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

March 25, 2024

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

March 18, 2024

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 6, 2024

Calls in 2024

Decks in 2024